Table 4.
OS, months | 95% CI | p value | |
---|---|---|---|
Model 1 | |||
Group A | |||
Durable response ≥3 months | |||
Present | 47.7 | 40.7–54.7 | <0.001 |
Absent | 21.8 | 15.6–28.0 | |
Durable response ≥6 months | |||
Present | 68.4 | undefined | <0.001 |
Absent | 26.7 | 22.5–31.0 | |
Group A + B | |||
Durable response ≥3 months | |||
Present | 47.7 | 42.6–52.8 | <0.001 |
Absent | 20.0 | 15.0–25.0 | |
Durable response ≥6 months | |||
Present | 68.5 | undefined | <0.001 |
Absent | 25.0 | 20.7–29.3 | |
Model 2 | |||
Group A | |||
Durable response ≥3 months | |||
Present | 32.4 | 25.3–39.6 | 0.014 |
Absent | 16.5 | 11.4–21.7 | |
Durable response ≥6 months | |||
Present | 41.6 | 19.5–63.6 | 0.057 |
Absent | 22.2 | 15.3–29.1 | |
Group A + B | |||
Durable response ≥3 months | |||
Present | 36.3 | 23.5–49.1 | <0.001 |
Absent | 15.5 | 12.2–18.8 | |
Durable response ≥6 months | |||
Present | 47.7 | 36.8–58.6 | 0.005 |
Absent | 21.0 | 16.3–25.6 | |
Model 3 | |||
Group A | |||
Durable response ≥3 months | |||
Present | 32.4 | 26.0–38.9 | 0.008 |
Absent | 15.1 | 13.0–17.3 | |
Durable response ≥6 months | |||
Present | 41.6 | 16.4–66.7 | 0.079 |
Absent | 20.1 | 14.9–27.0 | |
Group A + B | |||
Durable response ≥3 months | |||
Present | 36.3 | 24.7–47.9 | <0.001 |
Absent | 15.2 | 13.6–16.8 | |
Durable response ≥6 months | |||
Present | 50.8 | 28.7–72.9 | 0.007 |
Absent | 20.0 | 14.4–25.6 |
CI, confidence interval; HCC, hepatocellular carcinoma; OS, overall survival.